Corallopyronin A Amorphous Dispersion for Oral Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Corallopyronin A, a natural compound with antibacterial properties, is highly lipophilic and poorly soluble in water-based solvents, making it difficult to formulate into stable pharmaceutical products suitable for oral administration.
Innovation Solution
Embedding corallopyronin A in a water-soluble polymer such as polyvinylpyrrolidone or polyvinylpyrrolidone/vinylacetate copolymer to create an amorphous solid dispersion, which can be formulated into capsules, tablets, or other solid dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corallopyronin A is used as a pure compound, then it provides antibacterial properties, but it is highly lipophilic and poorly soluble in water-based solvents, making it unsuitable for oral administration
Solution Approach 1:
The patent embeds corallopyronin A in a water-soluble polymer matrix (polyvinylpyrrolidone or polyvinylpyrrolidone/vinylacetate copolymer) to create a composite formulation. This composite structure maintains the antibacterial activity of corallopyronin A while the polymer provides water solubility, enabling oral administration. The polymer acts as a carrier that solubilizes the lipophilic compound without compromising its biological activity.
Solution Approach 2:
The patent changes the physical state of corallopyronin A from pure crystalline form to an amorphous solid dispersion embedded in polymer. This parameter change from crystalline to amorphous state, combined with embedding in a water-soluble polymer, fundamentally alters the solubility characteristics while maintaining the compound's antibacterial properties.
2Reliability
If corallopyronin A is used as a pure compound, then it provides antibacterial properties, but it has a semisolid, sticky and oily consistency that is not usable for tableting or filling into capsules
Solution Approach 1:
The patent creates a composite solid formulation where corallopyronin A is embedded in a water-soluble polymer matrix. This composite structure transforms the semisolid, sticky, and oily consistency of pure corallopyronin A into a free-flowing solid material that can be easily manufactured into tablets and capsules. The polymer provides structural integrity and appropriate physical properties for pharmaceutical manufacturing.
Solution Approach 2:
The patent changes the physical state and consistency of corallopyronin A by embedding it in a polymer matrix. This transforms the compound from a semisolid, sticky, and oily substance into a stable solid formulation with appropriate flow and compression properties for tableting and capsule filling operations.
3Ease of operation
If corallopyronin A is formulated to improve solubility, then oral administration becomes possible, but stability of the formulation may be compromised
Solution Approach 1:
The patent uses a water-soluble polymer (polyvinylpyrrolidone or polyvinylpyrrolidone/vinylacetate copolymer) as a stabilizing matrix that embeds corallopyronin A. This composite structure provides both solubility enhancement for oral administration and stability protection. The polymer matrix prevents degradation of corallopyronin A while maintaining its solubility in aqueous environments.
Solution Approach 2:
The water-soluble polymer acts as an intermediary between corallopyronin A and the aqueous environment. It mediates the interaction by providing solubility without direct exposure of the lipophilic compound to water, thereby maintaining stability. The polymer protects corallopyronin A from degradation while enabling its dissolution and absorption in the gastrointestinal tract.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation enhances solubility and stability, allowing for effective oral administration with high bioavailability and stability, as demonstrated by increased absorption and bioavailability in vivo.
Implementation Method 1
the formulation comprises an amorphous solid dispersion of corallopyronin A embedded in a water-soluble polymer
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a solid or liquisolid formulation comprising corallopyronin A, wherein the formulation comprises an amorphous solid dispersion of corallopyronin A embedded in a water-soluble polymer or corallopyronin A loaded onto porous silica.